STOCK TITAN

NATIONAL HEALTHCARE (NHC) director sells 1,563 shares, retains options

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

NATIONAL HEALTHCARE CORP director Emil E. Hassan reported an open-market sale of 1,563 shares of common stock at $199.975 per share. After this transaction, he directly holds 71,532 shares. He also retains several stock option awards, each covering 7,500 underlying shares from 2022–2026 grants with exercise prices between $55.75 and $171.42 and expirations from 2027 to 2031.

Positive

  • None.

Negative

  • None.
Insider HASSAN EMIL E
Role Director
Sold 1,563 shs ($313K)
Type Security Shares Price Value
Sale Shares of Common Stock 1,563 $199.975 $313K
holding Option to Purchase Common Stock [2022 Grant] -- -- --
holding Option to Purchase Common Stock [2023 Grant] -- -- --
holding Option to Purchase Common Stock [2024 Grant] -- -- --
holding Option to Purchase Common Stock [2025 Grant] -- -- --
holding Option to Purchase Common Stock [2026 Grant] -- -- --
Holdings After Transaction: Shares of Common Stock — 71,532 shares (Direct); Option to Purchase Common Stock [2022 Grant] — 7,500 shares (Direct); Option to Purchase Common Stock [2023 Grant] — 7,500 shares (Direct); Option to Purchase Common Stock [2024 Grant] — 7,500 shares (Direct); Option to Purchase Common Stock [2025 Grant] — 7,500 shares (Direct); Option to Purchase Common Stock [2026 Grant] — 7,500 shares (Direct)
Footnotes (1)
Shares sold 1,563 shares Open-market sale of common stock
Sale price $199.975 per share Price for 1,563 NHC shares sold
Shares held after sale 71,532 shares Common stock directly owned post-transaction
2026 option grant strike $171.42 per share Option to purchase common stock [2026 Grant]
2025 option grant strike $94.66 per share Option to purchase common stock [2025 Grant]
Underlying shares per option grant 7,500 shares Each of 2022–2026 option grants
Earliest option expiration May 4, 2027 2022 option grant expiration date
Latest option expiration May 6, 2031 2026 option grant expiration date
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Option to Purchase Common Stock financial
"security_title": "Option to Purchase Common Stock [2026 Grant]""
exercise price financial
"conversion_or_exercise_price": "171.4200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2031-05-06T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did NHC director Emil E. Hassan report?

NHC director Emil E. Hassan reported an open-market sale of 1,563 shares of common stock. The shares were sold at a price of $199.975 per share, as reflected in the Form 4 insider trading disclosure.

How many NHC shares does Emil E. Hassan hold after the reported sale?

After the reported sale, Emil E. Hassan directly holds 71,532 shares of National Healthcare Corp common stock. This post-transaction balance is disclosed in the Form 4 as the total shares beneficially owned following the transaction.

At what price did Emil E. Hassan sell NHC shares in this Form 4?

The Form 4 shows that Emil E. Hassan sold NHC common shares at $199.975 per share. This price reflects the sale in an open-market or private transaction, as indicated by the transaction code description.

What stock options on NHC shares does Emil E. Hassan still hold?

He holds multiple options to purchase NHC common stock from 2022–2026 grants, each covering 7,500 underlying shares. Exercise prices range from $55.75 to $171.42 per share, with expiration dates between 2027 and 2031.

Does the Form 4 show any NHC share purchases by Emil E. Hassan?

The Form 4 lists one open-market sale of NHC common stock and no reported purchases. Other entries relate to existing option holdings rather than new acquisitions of common shares in the market.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HASSAN EMIL E

(Last)(First)(Middle)
100 VINE STREET

(Street)
MURFREESBORO TENNESSEE 37130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTHCARE CORP [ NHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Shares of Common Stock06/16/2026S1,563D$199.97571,532D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock [2022 Grant]$69.1905/05/202305/04/2027Common Stock7,5007,500D
Option to Purchase Common Stock [2023 Grant]$55.7505/04/202405/03/2028Common Stock7,5007,500D
Option to Purchase Common Stock [2024 Grant]$96.0305/09/202505/08/2029Common Stock7,5007,500D
Option to Purchase Common Stock [2025 Grant]$94.6605/08/202605/07/2030Common Stock7,5007,500D
Option to Purchase Common Stock [2026 Grant]$171.4205/07/202705/06/2031Common Stock7,5007,500D
Explanation of Responses:
/s/ Emil E. Hassan06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)